Arcus Biosciences is pioneering the development of combination therapies aimed at treating various forms of cancer. The company focuses on creating differentiated small molecules and antibodies that are designed to optimize their combinability, thereby enhancing the effectiveness of cancer treatments. Their clinical pipeline includes several investigational compounds, such as Domvanalimab (an anti-TIGIT antibody), Quemliclustat (a CD73 inhibitor), and Etrumadenant (a dual adenosine receptor antagonist). These molecules are being evaluated in various clinical trials for indications including lung, gastrointestinal, kidney, pancreatic, and colorectal cancers, with a strong emphasis on advancing these therapies from early-phase studies to commercialization.

In addition to their innovative drug development, Arcus emphasizes collaboration with the cancer community to expedite the participation in global clinical trials and bring new therapies to patients more swiftly. Their partnerships with major pharmaceutical companies, such as Gilead and AstraZeneca, facilitate the co-development and commercialization of next-generation cancer immunotherapies. This collaborative approach, combined with their focus on specific biological mechanisms of cancer, positions Arcus at the forefront of cancer treatment innovation, striving to improve patient outcomes through effective combination therapies.

United States

Arcus Biosciences is an exciting growth company founded on the vision of creating best-in-class cancer therapies. We are an oncology-focused biopharmaceutical company leveraging its deep cross-discipline expertise to discover highly differentiated therapies and develop a broad portfolio of novel combinations addressing significant unmet needs.

We are located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub. Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus is an ambitious undertaking, and we fully expect our company to become a force in the discovery, development and commercialization of novel therapies for the treatment of cancer. Our employees enjoy operating in an exceptionally dynamic and cooperative environment in which the “rule book” has not yet been written. 

Cancer

Digestive System Diseases

Endocrine System Diseases

Kidney Diseases

Lung Diseases

Arcus Biosciences 

Non-small cell lung carcinoma

Domvanalimab (AB154), &nbsp;an anti-TIGIT monoclonal antibody and new potential immuno-oncology &nbsp;backbone therapy, is in a three-arm randomized Phase 2 study for &nbsp;first-line treatment of PD-L1-high metastatic non-small cell lung cancer &nbsp;evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and &nbsp;domvanalimab plus AB928 with zimberelimab.

Domvanalimab + Zimberelimab + Chemo vs. Pembrolizumab + Chemo

Gastroesophageal adenocarcinomas

Gastroesophageal junction tumors

Gastrointestinal stromal tumors

Domvanalimab + Zimberelimab + Chemo v.s. Nivolumab + Chemo

Renal cell carcinoma

Solid tumor/s

AB521, A small molecule inhibitor of the hypoxic transcriptional regulator HIF-2⍺ has demonstrated potent antitumor activity in xenograft models of cancer
HIF-2⍺ is a key transcriptional regulator that helps drive the growth of many solid tumors. HIF-2⍺ is regulated through degradation and is normally only stably expressed and accumulated in cells under hypoxic conditions. Hypoxic tumors correlate highly with upregulation of the adenosine pathway, suggesting that targeting the adenosine pathway may enhance the antitumor activity of AB521.

Casdatifan + Cabozantinib

Domvanalimab + Durvalumab v.s. Durvalumab

Pancreatic ductal adenocarcinoma

Quemliclustat + Gemcitabine/Nab-Paclitaxel v.s. Gemcitabine/Nab-Paclitaxel

Casdatifan + Cabozantinib v.s. Cabozantinib

Colorectal cancer

Metastatic colorectal cancer

ETRUMADENANT (AB928): THE FIRST AND ONLY DUAL ADENOSINE RECEPTOR ANTAGONIST TARGETING A2aR AND A2bR
Adenosine is a powerful immunosuppressive substance produced inside tumors as a result of rapid cancer cell turnover and, in some cases, in connection with certain anti-tumor interventions, such as chemotherapy and radiation.
The A2a/A2b&nbsp;receptors, expressed on the surface of immune cells, mediate the immunosuppressive effects of adenosine.

Etrumadenant + Zimberelimab + mFOLFOX v.s. Standard of care

ETRUMADENANT (AB928): THE FIRST AND ONLY DUAL ADENOSINE RECEPTOR ANTAGONIST TARGETING A2aR AND A2bR
<ul class="font_8">
 <li>Adenosine is a powerful immunosuppressive substance produced inside tumors as a result of rapid cancer cell turnover and, in some cases, in connection with certain anti-tumor interventions, such as chemotherapy and radiation.</li>
 <li>The A2a/A2b&nbsp;receptors, expressed on the surface of immune cells, mediate the immunosuppressive effects of adenosine.</li>
</ul>

Domvanalimab +/- Zimberelimab +/- Sacituzumab govitecan-hziy or other combos

Esophageal cancer

Gastric cancer

Domvanalimab is the first and most clinically advanced Fc-silent investigational monoclonal antibody that is specifically designed with Fc-silent properties to block and bind to the T-cell immunoreceptor with Ig and ITIM domains (TIGIT), a checkpoint receptor on immune cells that acts as a brake on the anticancer immune response. By binding to TIGIT with Fc-silent properties, domvanalimab is believed to work by freeing up immune-activating pathways and activate immune cells to attack and kill cancer cells without depleting the peripheral regulatory T cells important in avoiding immune-related toxicity.
 
Combined inhibition of both TIGIT and programmed cell death protein-1 (PD-1) is believed to significantly enhance immune cell activation, as these checkpoint receptors play distinct, complementary roles in anti-tumor activity. Domvanalimab is being evaluated in combination with anti-PD-1 monoclonal antibodies, including zimberelimab, as well as other investigational cancer immunotherapies and A2a/A2b adenosine receptor antagonist etrumadenant, in multiple ongoing and planned early and late-stage clinical studies in various tumor types.

Domvanalimab +/- Zimberelimab +/- Chemo

Pancreatic cancer

Etrumadenant + Atezolizumab

Adenosine is a powerful immunosuppressive substance produced inside tumors as a result of rapid cancer cell turnover and, in some cases, in connection with certain anti-tumor interventions, such as chemotherapy and radiation.
The A2a/A2b&nbsp;receptors, expressed on the surface of immune cells, mediate the immunosuppressive effects of adenosine.

Quemliclustat +/- Zimberelimab

Domvanalimab +/- Zimberelimab +/- Quemliclustat +/- Chemo

Advanced malignancies

AB598

AB801

Casdatifan + Zanzalintinib

Castration-resistant prostate cancer

Prostate cancer

Adenosine is a powerful immunosuppressive substance produced inside tumors as a result of rapid cancer cell turnover and, in some cases, in connection with certain anti-tumor interventions, such as chemotherapy and radiation.
The A2a/A2b&nbsp;receptors, expressed on the surface of immune cells, mediate the immunosuppressive effects of adenosine.
Etrumadenant is designed to maximally inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes (mainly CD8+ T cells and NK cells) and myeloid cells (dendritic cells, macrophages), mediated by A2a/A2b, respectively. A2bR is also upregulated by certain cancer cells, such as in prostate cancer and KRAS-mutated cancers. As a result, etrumadenant may uniquely block adenosine’s immunosuppressive and cancer cell-intrinsic effects.

Arcus Biosciences

Company Details